SecBot SecBot
8-K ·Filed May 11, 2026

APGE

Apogee Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001193125-26-215683
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong cash position and positive clinical data de-risk the pipeline significantly. The key catalyst to watch is the APEX Part B 16-week data expected in Q2 2026, which will determine the induction dosing regimen for Phase 3 trials. The stock should trade on clinical data readouts and pipeline expansion announcements rather than quarterly financial results.

DirectionBullish
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Apogee Therapeutics reported Q1 2026 results with a net loss of $74.1M, wider than the $55.3M loss in Q1 2025, driven by increased R&D and G&A spending. The key positive was the strong cash position of $1.3B following a $403M upsized public offering, extending runway into 2029, and positive pipeline updates including APEX Phase 2 Part A 52-week data showing durable maintenance with quarterly or less frequent dosing.

Key Facts

  • Cash, cash equivalents, and marketable securities totaled $1.3B as of March 31, 2026, up from $902.9M at year-end 2025
  • Completed $403M upsized public equity offering following positive Phase 2 APEX Part A readout
  • Net loss widened to $74.1M in Q1 2026 from $55.3M in Q1 2025, driven by higher R&D ($60.8M vs $46.4M) and G&A ($22.0M vs $16.7M) expenses
  • APEX Phase 2 Part A 52-week data showed durable maintenance: 75-85% of Week 16 EASI-75 responders maintained response at Week 52 with every 3- or 6-month dosing
  • Phase 3 initiation in atopic dermatitis expected in H2 2026; APEX Part B 16-week data expected in Q2 2026
  • Positive Phase 1b asthma results reported in January 2026; expansion into asthma and EoE trials planned
  • Cash runway extended into 2029, through planned BLA filing for zumilokibart in AD

Financial Impact

Net loss of $74.1M in Q1 2026 vs $55.3M in Q1 2025; cash position strengthened to $1.3B from $902.9M

cash_positionnet_lossr&d_expensesg&a_expenses

Risk Factors

  • Clinical trial failure or disappointing data in upcoming readouts (APEX Part B, APG279 head-to-head)
  • Dilution risk from potential future equity offerings to fund Phase 3 trials and commercialization
  • Competitive pressure from existing therapies like DUPIXENT and other IL-13/TSLP targeting programs
  • Regulatory risk: BLA filing and approval are not guaranteed

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
83% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-215683
Document: apge-20260511.htm0001193125-26-215683
Document: 0001193125-26-215683-index-headers.html0001193125-26-215683
Document: 0001193125-26-215683-index.html0001193125-26-215683
Document: 0001193125-26-215683.txt0001193125-26-215683
8-K Data (Synthetic)0001193125-26-215683

Track record

31 reports on APGE

Performance horizon

9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.

Filters
  1. Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
  2. Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
  3. Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
  4. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
  5. Aug 10, 202614w ago 8-K Bullish 8/10 No price data
  6. Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
  7. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
  8. Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
  9. Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
  10. Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens Wed (10h 25m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026